
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc. is positioned for positive growth, driven by anticipated increases in revenue due to accelerated market share gains in Minimally Invasive Glaucoma Surgery (MIGS) and enhanced adoption of the TearCare System. The company's commitment to its Surgical Glaucoma business, which is expected to align with overall market growth trends, provides a solid foundation for sustaining revenue streams. Furthermore, improvements in earnings per share forecasts for 2025 and 2026 reflect an optimistic outlook, illustrating the company's progress towards achieving profitability while maintaining projected revenues of $75 million and $82 million in those years.
Bears say
Sight Sciences Inc. has reiterated its 2025 revenue guidance at $72-76 million, while anticipating a mid-single-digit percentage decline in year-over-year revenue for the Surgical Glaucoma segment in the third quarter of 2025. The company faces several challenges, including increasing competition in the minimally invasive glaucoma surgery (MIGS) market, slow progress in securing insurance coverage for its TearCare system, and ongoing issues with cash burn. Additionally, management has adjusted its 2025 operating expense guidance down to $95-99 million from $101-105 million, despite projecting $12 million in annualized savings from workforce reductions, indicating concerns about financial stability.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares